LG Group has decided to embark on joint AI research and development with The Jackson Laboratory, a world-renowned genome research institution based in the United States, to unlock the secrets of Alzheimer’s disease and cancer.LG AI Research and The Jackson Laboratory have signed a recent contract fo
The Korea Institute of Ocean Science and Technology (KIOST) announced on Oct. 18 that it has discovered a peptide, or short chain of amino acids linked by peptide bonds, that inhibits the formation of amyloid-β plaques, a known cause of dementia, in the venomous protein of jellyfish. The institute h
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.1Q23 operating loss decreases on cost control despite sales dropPsomagen continued in the red in 1Q23 with sales of USD6.52mn (-11.2% YoY) on standalone basis. Sales fell as orders were slashed by a m
The Korea Advanced Institute of Science and Technology (KAIST) announced on May 8 that a KAIST research team led by Professor Jung In-kyung of the School of Life Sciences has created the world’s first single-cell three-dimensional epigenome map of Parkinson’s disease-onset brain tissue and proposed
The Incheon Free Economic Zone (IFEZ) used to be an island, sea, tidal flat, and reclaimed land, but now it has been transformed into an ultra-modern city with sky-high skyscrapers and a population of 410,000. After being designated as Korea's first free economic zone in 2003, a great change has
JW Group announced on Nov. 1 that it has signed a joint research contract with KURE.AI Therapeutics, a U.S. biotech venture company, to develop innovative anticancer therapies based on artificial intelligence (AI).Under this contract, JW Pharmaceutical and JW CreaGene will start R&D activities for t
GC Labs and the three subsidiaries of GC Pharma (GC Pharma MS, GC Cell and GC Genome) announced on July 8 that the 24th International Congress of Clinical Chemistry and Laboratory Medicine was successfully wrapped up in Seoul.The three subsidiaries and the medical foundation participated in the cong
Daewoong Pharmaceutical announced on May 3 that it has signed an agreement with DCGen, a clinical genome analysis technology company, at the end of April to promote global business for a multigene test kit for breast cancer prognosis prediction based on next-generation sequencing (NGS).Under this ag
MedPacto, Inc., a genome-based drug discovery and clinical-stage biotechnology company, announced on Feb. 14 that it has entered into a clinical trial agreement with University Hospitals Cleveland Medical Center in the United States to pursue an investigator-initiated clinical trial in patients with
MedPacto, Inc., a genome-based drug discovery and clinical-stage biotechnology company, announced on Feb. 11 that it has partnered with HITS, an artificial intelligence (AI) drug discovery company, to co-develop new drugs.Under the terms of the agreement, the two companies will practice drug develop
Genome and Co., a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA of Germany and Pfizer Inc. with the aim of developing the world’s first immuno-oncology microbiome therapeutic.The collaboration
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Pharma/bio tend to outperform broader markets from the start of the yearPharmaceutical/bio stocks usually outperform the broader markets from the start of the
Samsung SDS said on Dec. 20 that it has topped the iDASH 2020 secure genome analysis competition with its outstanding homomorphic encryption technology. Homomorphic encryption is a technology that analyzes and processes data in an encrypted state in order to protect sensitive information such as per
Genome & Co., a global pioneer in microbiome therapeutics, has initiated clinical trials of GEN-001, an anti-cancer microbiome therapeutic (NCT04601402), in the United States.GEN-001 is an oral microbiome therapeutic candidate, and in this clinical trial, it will be administered to American patients
Genome & Co. (KONEX: 314130), a Korean biotechnology company developing innovative therapeutics in immune-oncology, announced on April 20 that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for GEN-001 for combination treatment with avelumab (
Kim Bitnaeri, a renowned life science professor at Seoul National University, has analyzed the RNA transcript of the virus that causes COVID-19 infections for the first time in the world, paving the way for the development of high-precision reagents and therapeutic drugs for the novel coronavirus.Th
The 2020 JP Morgan Healthcare Conference, the world’s largest healthcare investment symposium for the pharmaceutical and biotech industry, opened in San Francisco, the United States, on Jan. 13 (local time), with some 1,500 pharma companies from 40 countries around the world participating. About 30
Korean biotechnology startups are seeking to enter the U.S. market, the largest biopharmaceutical market in the world.The Korea Trade-Investment Promotion Agency (KOTRA) said on May 26 that 12 Korean biotechnology companies will participate in the 2019 Bio International Convention, which is a large-
Precision medical biotechnology company Macrogen has been designated by the Ministry of Food and Drug Safety (MFDS) as a clinical trial specimen analysis institution, which performs specimen analysis of blood and urine collected from clinical test subjects.Macrogen can now perform next-generation se
Direct to customer (DTC) genetic testing companies are expanding their testing areas to diseases and diverse wellness fields on the back of the government’s “sandbox” deregulation initiative.The Ministry of Trade, Industry, and Energy designated three additional companies, DNA Link, Theragen Etex an